항암 및 항암보조제
Oncology Portal | News
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer
Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer
At ASCO 2019, New Studies Provide Hope for Patients With Metastatic Breast Cancer
HER2+ Breast Cancer: Neratinibs Role as Adjuvant Therapy
Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer
https://www.onclive.com/onclive-tv/dr-esteva-discusses-neratinib-updates-in-her2-breast-cancer
EMA approves neratinib for early breast cancer
https://www.onclive.com/web-exclusives/neratinib-approaches-eu-approval-for-her2-breast-cancer
Copyright 2020 - BIXINK | Terms of Use | Contact
서울특별시 강남구 강남대로 292 6층 [06258]
6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea